Top

Published in:

01-02-2002 | Original Research Article

Evidence for Therapeutic Equivalence of Lansoprazole 30mg and Esomeprazole 40mg in the Treatment of Erosive Oesophagitis

Authors: Dr Colin W. Howden, E. David Ballard II, Weining Robieson

Published in: Clinical Drug Investigation | Issue 2/2002

Abstract

Objective: To compare the effectiveness of lansoprazole 30mg once daily and esomeprazole 40mg once daily on healing and symptom relief in patients with erosive oesophagitis.

Design: Phase IV, randomised, double-blind, active-controlled, multicentre study.

Patients and participants: 284 patients with endoscopically confirmed erosive oesophagitis (grade ≥2).

Methods: Patients were randomised to treatment with lansoprazole or esomeprazole. The primary efficacy endpoint was the healing of erosive oesophagitis (defined as grade 0 or 1) at week 8. Healing rates at week 4 and the percentages of patients reporting no daytime or night-time heartburn after 1 day, 3 days and 1 week of treatment, as well as the rate of healing or improvement of oesophagitis by two grades, were also analysed.

Results: Healing rates and 95% confidence intervals (CIs) at week 8 were 91.4% (85.4, 95.5%) for lansoprazole 30mg once daily and 89.1% (82.7, 93.8%) for esomeprazole 40mg once daily, respectively. For any baseline grade, greater than 90% of lansoprazole-treated and 81% of esomeprazole-treated patients exhibited healing or improvement of erosive oesophagitis by two grades from baseline to week 8. Healing rates at week 4 were also comparable: 77.0% (95% CI 69.1, 83.7%) for lansoprazole 30mg and 78.3% (95% CI 70.4, 84.8%) for esomeprazole 40mg. The percentages of heartburn-free patients after 1 day, 3 days and 1 week of treatment were slightly higher for lansoprazole compared with esomeprazole, although the differences did not reach statistical significance (p > 0.05). Both treatments were well tolerated.

Conclusions: In erosive oesophagitis, lansoprazole 30mg once daily and esomeprazole 40mg once daily are equally effective in healing erosions and relieving heartburn.

National Institutes of Health National Digestive Diseases Information Clearinghouse. Gastroesophageal reflux disease (hiatal hernia and heartburn) [online]. Available from URL: http://www.niddk.nih.gov/health/digest/pubs/heartbrn/heartbrn.htm [Accessed 2002 Jan 18]

Locke GR, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997; 112: 1448–56PubMedCrossRef

Nebel OT, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux: incidence and precipitating factors. Am J Dig Dis 1976; 21: 953–6PubMedCrossRef

DeVault KR, Castell DO. Current diagnosis and treatment of gastroesophageal reflux disease. Mayo Clin Proc 1994; 69: 867–6PubMedCrossRef

Rai A, Orlando R. Gastroesophageal reflux disease. Curr Opin Gastroenterol 1998; 14: 326–3CrossRef

Thomson AB, Chiba N, Armstrong D, et al. The Second Canadian Gastroesophageal Reflux Disease Consensus: moving forward to new concepts. Can J Gastroenterol 1998; 12: 551–6PubMed

Schnell T, Sontag S, Wanner J, et al. Endoscopic screening for Barrett’s esophagus, esophageal adenocarcinoma and other mucosal changes in ambulatory subjects with symptomatic gastroesophageal reflux [abstract]. Gastroenterology 1985; 88: 1576

Behar J, Biancani P, Sheahan DG. Evaluation of esophageal tests in the diagnosis of reflux esophagitis. Gastroenterology 1976; 71: 9–15PubMed

Johansson KE, Ask P, Boeryd B, et al. Oesophagitis, signs of reflux, and gastric acid secretion in patients with symptoms of gastro-oesophageal reflux disease. Scand J Gastroenterol 1986; 21: 837–47PubMedCrossRef

10.

Sontag SJ. Rolling review: gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1993; 7: 293–312PubMedCrossRef

11.

Fennerty MB. Medical treatment of gastroesophageal reflux in the managed care environment. Semin Gastrointest Dis 1997; 8: 90–9PubMed

12.

Fennerty MB. The economics of therapy of gastroesophageal reflux disease. Gastroenterol Int 1997; 10: 126–30

13.

Dimenas E. Methodological aspects of evaluation of quality of life in upper gastrointestinal diseases. Scand J Gastroenterol Suppl 1993; 199: 18–21CrossRef

14.

Gamliel Z. Incidence, epidemiology, and etiology of esophageal cancer. Chest Surg Clin N Am 2000; 10: 441–50PubMed

15.

Brewster DH, Fraser LA, McKinney PA, et al. Socioeconomic status and risk of adenocarcinoma of the oesophagus and cancer of the gastric cardia in Scotland. Br J Cancer 2000; 83: 387–90PubMedCrossRef

16.

Botterweck AA, Schouten LJ, Volovics A, et al. Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol 2000; 29: 645–54PubMedCrossRef

17.

Lagergren J, Bergstrom R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 825–31PubMedCrossRef

18.

Bell NJV, Burget D, Howden CW, et al. Appropriate acid suppression for the management of gastroesophageal reflux disease. Digestion 1992; 51 Suppl 1: 59–67PubMedCrossRef

19.

Hetzel DJ, Dent J, Reed WD, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988; 95: 903–12PubMed

20.

Wesdorp ICE, Dekker W, Festen HPM. Efficacy of famotidine 20 mg twice a day versus 40 mg twice a day in the treatment of erosive or ulcerative reflux esophagitis. Dig Dis Sci 1993; 38: 2287–93PubMedCrossRef

21.

Sandmark S, Carlsson R, Fausa O, et al. Omeprazole or ranitidine in the treatment of reflux esophagitis. Results of a double-blind, randomized, Scandinavian multicenter study. Scand J Gastroenterol 1988; 23: 625–32PubMedCrossRef

22.

Richter JE, Sabesin SM, Kogut DG, et al. Omeprazole versus ranitidine or ranitidine/metoclopramide in poorly responsive symptomatic gastroesophageal reflux disease. Am J Gastroenterol 1996; 91: 1766–72PubMed

23.

Lundell L, Backman L, Ekstrom P, et al. Omeprazole or high-dose ranitidine in the treatment of patients with reflux oesophagitis not responding to ’standard doses’ of H2-receptor antagonists. Aliment Pharmacol Ther 1990; 4: 145–55PubMedCrossRef

24.

Robinson M, Sahba B, Avner D, et al. Comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Aliment Pharmacol Ther 1995; 9: 25–31PubMedCrossRef

25.

Jones RH, Baxter G. Lansoprazole 30 mg daily versus ranitidine 150 mg bd in the treatment of acid-related dyspepsia in general practice. Aliment Pharmacol Ther 1998; 11: 541–6CrossRef

26.

Gough AL, Long RG, Cooper BT, et al. Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis. Aliment Pharmacol Ther 1996; 10: 529–39PubMedCrossRef

27.

Castell DO, Richter JE, Robinson M, et al. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. Am J Gastroenterol 1996; 91: 1749–57PubMed

28.

Huang JQ, Sridhar S, Hunt RH. Are there any differences in symptom relief and healing esophagitis between proton pump inhibitors: a meta-analysis of comparative trials. Gut 1999; 45: P513CrossRef

29.

Sharma VK, Leontiadis GI, Howden CW. Meta-analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis. Aliment Pharmacol Ther 2001; 15: 227–31PubMedCrossRef

30.

Richter JE, Kahrilas PJ, Sontag SJ, et al. Onset of heartburn relief comparing lansoprazole with omeprazole: results of a randomized, controlled trial in erosive esophagitis patients. Am J Gastroenterol 2001; 96: 656–5PubMedCrossRef

31.

Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001; 96: 656–65PubMedCrossRef

32.

Kahrilas PJ, Falk GW, Johnson DA, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. Aliment Pharmacol Ther 2000; 14: 1249–58PubMedCrossRef

33.

Esomeprazole (Nexium) [package insert]. Wilmington (DE): Astra Zeneca, 2001 Feb

34.

VanEiteren PH. On the combination of independent two sample test of Wilcoxon. Bull Inst Intern Statis 1960; 37: 351–61

35.

Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole provides more effective healing than lansoprazole in GERD patients with erosive esophagitis [abstract]. Am J Gastroenterol 2001;96: S7

36.

Robinson M, Lanza F, Avner D, et al. Effective maintenance treatment of reflux esophagitis with low dose lansoprazole: a randomized, double-blind, placebo controlled trial. Ann Intern Med 1996; 124: 859–67PubMed

37.

Sontag SJ, Kogut DG, Fleischmann R, et al. Lansoprazole prevents recurrence of erosive reflux esophagitis previously resistant to H2RA therapy. Am J Gastroenterol 1996; 91: 1758–65PubMed

38.

Delhotal-Landes B, Flouvat B, Duchier J, et al. Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity. Eur J Clin Pharmacol 1993; 45: 367–71PubMedCrossRef

39.

Hassan-Alin M, Rohss K, Andersson T, et al. Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects [abstract]. Gastroenterology 2000; 118 (4 Pt 2): A16.328

40.

Tolman K, Sander SW, Buchi KN, et al. The effects of oral doses of lansoprazole and omeprazole on gastric pH. J Clin Gastroenterol 1997; 24: 65–70PubMedCrossRef

41.

Thoring M, Hedenstrom H, Eriksson LS. Rapid effect of lansoprazole on intragastric pH: a crossover comparison with omeprazole. Scand J Gastroenterol 1999; 34: 341–5PubMedCrossRef

42.

Hatlebakk JG, Berstad A, Carling L, et al. Lansoprazole vesus omeprazole in short-term treatment of reflux oesophagitis: results of a Scandinavian multicentre trial. Scand J Gastroenterol 1993; 28: 224–8PubMedCrossRef

43.

Mee AS, Rowley JL, Lansoprazole Clinical Research Group. Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole. Aliment Pharmacol Ther 1996; 10: 757–63PubMedCrossRef

Title: Evidence for Therapeutic Equivalence of Lansoprazole 30mg and Esomeprazole 40mg in the Treatment of Erosive Oesophagitis
Authors: Dr Colin W. Howden
E. David Ballard II
Weining Robieson
Publication date: 01-02-2002
Publisher: Springer International Publishing
Published in: Clinical Drug Investigation / Issue 2/2002
Print ISSN: 1173-2563
Electronic ISSN: 1179-1918
DOI: https://doi.org/10.2165/00044011-200222020-00004

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Evidence for Therapeutic Equivalence of Lansoprazole 30mg and Esomeprazole 40mg in the Treatment of Erosive Oesophagitis

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2002

Sore Throat Treatment during Pregnancy

Retrospective Study of Outcomes in Hyalgan®-Treated Patients with Osteoarthritis of the Knee

Review of the Pharmacological Properties and Clinical Usefulness of Muscarinic Agonists for Xerostomia in Patients with Sjögren’s Syndrome

Combination of Intermittent Cyclical Etidronate and Hormone Replacement Therapy for Postmenopausal Non-Responders to Estrogen

Indinavir Pharmacokinetics during Different Phases of the Menstrual Cycle in HIV-Infected Women

Bioavailability of Budesonide Delivered by the Clickhaler® and Turbuhaler® Dry Powder Inhalers in Healthy Volunteers